Business

IIE Digital Desk : Cipla Ltd., a leading Indian pharmaceutical company, reported a robust 30% year-on-year increase in consolidated net profit for the fourth quarter of fiscal year 2024-25, reaching ₹1,222 crore, up from ₹939 crore in the same period last year. The company's revenue from operations also saw a significant rise of 9%, totaling ₹6,730 crore compared to ₹6,163 crore in Q4 FY24 .

The company's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for the quarter stood at ₹1,537 crore, marking a 16.8% increase from the previous year. The EBITDA margin improved by 184 basis points to 22.84%, reflecting enhanced operational efficiency .

In recognition of its 90th anniversary, Cipla's board of directors declared a final dividend of ₹13 per equity share for FY25, along with a special dividend of ₹3 per share, bringing the total dividend to ₹16 per equity share of face value ₹2 each. The record date for determining shareholder eligibility is set for June 27, 2025 .

Cipla's Managing Director and Global CEO, Umang Vohra, attributed the strong performance to steady growth in key markets and product segments. He highlighted that the company's U.S. business achieved an all-time high annual revenue of $934 million, while the 'One Africa' region recorded a 12% year-on-year growth in USD terms. Emerging Markets and Europe also delivered substantial revenue growth of 15% year-on-year, driven by a focused market strategy .

For the full fiscal year 2024-25, Cipla reported a consolidated net profit of ₹5,273 crore, up 28% from the previous year, with revenue increasing by 8% to ₹27,548 crore .

Despite global challenges, including potential U.S. tariffs on Indian pharmaceuticals, Cipla remains optimistic about its growth trajectory. The company continues to focus on expanding its key markets, building flagship brands, investing in future pipelines, and addressing regulatory matters to sustain its growth momentum .